 SYDNEY, Australia, Nov. 02, 2020 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce more mature interim data from its phase II TACTI-002 study of eftilagimod alpha efti has been accepted as a late breaker poster presentation and poster walk for highly scored abstracts at the Society for Immunotherapy of Cancer SITC 35th Anniversary 2020 Annual Meeting, which is taking place as a virtual event from 9-14 November, US Eastern Standard Time US EST. 